Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what guidance his Department provides on when a mental capacity review should be carried out on a patient.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

The Mental Capacity Act 2005 (MCA) is designed to protect and empower people who lack the mental capacity to make a decision themselves. It says that every person must be presumed to have capacity to make the decision in question unless it is established otherwise, and sets out a two-stage test to establish if a person can make specific decisions regarding their care and treatment. Capacity assessments are done locally, and data is not collated or held centrally on how many assessments are carried out.

The Deprivation of Liberty Safeguards (DoLS) is a procedure prescribed in law under the MCA when a person who lacks mental capacity to consent to their care or treatment is being deprived of their liberty in a care home or hospital in order to keep them safe from harm. DoLS assessments data is collated and published, the most recent data available is for 2023/24.

In 2023/24 there were 323,870 DoLS applications completed, 145,945 fully assessed, 15,270 closed partially assessed, 162,655 closed without assessments, and 123,790 not completed at year end.

The MCA code of practice gives guidance to people who work with, or care for, people who can’t make decisions for themselves, including when a mental capacity assessment should be carried out, and by whom. Government is clear that professionals applying the MCA are expected to keep up to date with guidance and caselaw, and to correctly use the principles within the act.

In October 2025 we announced our intention to run a joint consultation with the Ministry of Justice to consult on Liberty Protection Safeguards and an updated draft of the Code of Practice in 2026.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how many mental capacity assessments have been carried out on patients in each of the last five years.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

The Mental Capacity Act 2005 (MCA) is designed to protect and empower people who lack the mental capacity to make a decision themselves. It says that every person must be presumed to have capacity to make the decision in question unless it is established otherwise, and sets out a two-stage test to establish if a person can make specific decisions regarding their care and treatment. Capacity assessments are done locally, and data is not collated or held centrally on how many assessments are carried out.

The Deprivation of Liberty Safeguards (DoLS) is a procedure prescribed in law under the MCA when a person who lacks mental capacity to consent to their care or treatment is being deprived of their liberty in a care home or hospital in order to keep them safe from harm. DoLS assessments data is collated and published, the most recent data available is for 2023/24.

In 2023/24 there were 323,870 DoLS applications completed, 145,945 fully assessed, 15,270 closed partially assessed, 162,655 closed without assessments, and 123,790 not completed at year end.

The MCA code of practice gives guidance to people who work with, or care for, people who can’t make decisions for themselves, including when a mental capacity assessment should be carried out, and by whom. Government is clear that professionals applying the MCA are expected to keep up to date with guidance and caselaw, and to correctly use the principles within the act.

In October 2025 we announced our intention to run a joint consultation with the Ministry of Justice to consult on Liberty Protection Safeguards and an updated draft of the Code of Practice in 2026.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will set out the agreed definition of being housebound that is used by the NHS; and under what circumstances is a person's status from being classed as housebound.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

It is the responsibility of the commissioner to ensure patients registered with a general practice (GP) have access to urgent care when they are at home and unable to attend the practice they are registered with.

Under the GP Contract, GPs are required to provide services to a patient outside of practice premises, for instance via a home visit, in instances where the practice considers that a consultation is required, and it would be inappropriate for the patient to attend the practice.

Commonly, a patient is considered housebound if they cannot leave their home environment due to physical or psychological illness.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the government actions requested by the Royal College of Midwives as part of the "Safe Staffing = Safe Care" campaign.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department, NHS England, and the Nursing Midwifery Council are urgently working to ensure that midwifery training consistently delivers modern maternity care that respects a woman’s choice and individual circumstances.

We will introduce a new set of standards for modern employment in April 2026 to deliver our ambition to make the National Health Service the best place to work. We are committed to tackling the retention and recruitment challenges that face the NHS. As of November 2025, there were 25,530 full time equivalent midwives working in NHS trusts and other core organisations in England. This is an increase of 824, or 3.3%, compared to November 2024. We are also investing over £149 million through the 2025/26 Estates Safety Fund to address critical safety risks on the maternity estate, enabling better care for mothers and their newborns.

In addition, Baroness Amos is leading an independent investigation into NHS maternity and neonatal care. This includes understanding the experience of staff and healthcare professionals delivering care at all stages of the maternity and neonatal care pathway and how they can best be supported in providing high-quality, safe, and compassionate care. My Rt Hon. Friend, the Secretary of State for Health and Social Care, will chair a maternity and neonatal taskforce that will address the recommendations of the investigation by developing a national action plan to drive improvements across maternity and neonatal care.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what is the final membership of the National Maternity and Neonatal Taskforce; and what is the date of the first meeting of that taskforce; whether that taskforce will publish further findings after spring 2026.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The membership of the National Maternity and Neonatal Taskforce is currently being finalised. The first meeting of the taskforce will be held in early spring.

The taskforce will publish a national action plan to drive improvements across maternity and neonatal care in due course, following publication of Baroness Amos’ independent investigation’s final report and recommendations.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps the national maternity and neonatal investigation team is taking to ensure full representation of staff views in its work, including through a call for evidence at NHS trust level.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Following a meeting with West Mercia Police about the detail and schedule of their ongoing investigation, Baroness Amos concluded that the Shrewsbury and Telford Hospital NHS Trust should be removed from the National Maternity and Neonatal Investigation.

Leeds Teaching Hospitals NHS Trust was removed from the list of trusts under review as part of the national investigation following my Rt Hon. Friend, the Secretary of State for Health and Social Care’s decision to commission a separate independent maternity inquiry on 20 October.

The Call for Evidence for the National Maternity and Neonatal Investigation was launched in January 2026, and the investigation has encouraged families in Shrewsbury and Telford, and Leeds to participate.

On 26 January 2026, the Independent Maternity and Neonatal Investigation launched a Workforce Call for Evidence. This is open specifically to all those who work in the maternity and neonatal care pathway and is a separate to the public call for evidence. It takes the form of a short online survey and focuses on the experiences of staff delivering care across the maternity and neonatal pathway and how best to support teams to provide high-quality, safe, and compassionate care. Findings will inform the investigation’s national recommendations, due for publication in spring 2026.

Information about how to access the workforce survey has been distributed to all NHS trusts and the investigation is asking them to cascade the link to all maternity and neonatal staff groups. It is currently live and will be open for six weeks, closing on 9 March 2026.

Baroness Amos is also meeting the senior team in each of the 12 trusts and staff panels are also being held on site.

A list of leaders for national organisations, including statutory, Arm’s Length Bodies, and the voluntary and charitable sector, is being developed by the National Maternity and Neonatal Investigation. Leaders of these organisations will be invited to a formal interview with the Chair, Director of investigation, and a member of the Expert Panel.

The National Maternity and Neonatal Investigation is also gathering evidence from organisations. Organisations and other individuals, for instance researchers, wishing to submit evidence to the investigation can submit this directly by email to the investigation mailbox. The deadline for all evidence submissions is 17 March 2026.

Question to the Department of Health and Social Care:

To ask His Majesty's Government who was responsible for the decision to remove (1) Shrewsbury and Telford Hospital NHS Trust, and (2) Leeds Teaching Hospitals NHS Trust, from the scope of the national maternity and neonatal investigation.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Following a meeting with West Mercia Police about the detail and schedule of their ongoing investigation, Baroness Amos concluded that the Shrewsbury and Telford Hospital NHS Trust should be removed from the National Maternity and Neonatal Investigation.

Leeds Teaching Hospitals NHS Trust was removed from the list of trusts under review as part of the national investigation following my Rt Hon. Friend, the Secretary of State for Health and Social Care’s decision to commission a separate independent maternity inquiry on 20 October.

The Call for Evidence for the National Maternity and Neonatal Investigation was launched in January 2026, and the investigation has encouraged families in Shrewsbury and Telford, and Leeds to participate.

On 26 January 2026, the Independent Maternity and Neonatal Investigation launched a Workforce Call for Evidence. This is open specifically to all those who work in the maternity and neonatal care pathway and is a separate to the public call for evidence. It takes the form of a short online survey and focuses on the experiences of staff delivering care across the maternity and neonatal pathway and how best to support teams to provide high-quality, safe, and compassionate care. Findings will inform the investigation’s national recommendations, due for publication in spring 2026.

Information about how to access the workforce survey has been distributed to all NHS trusts and the investigation is asking them to cascade the link to all maternity and neonatal staff groups. It is currently live and will be open for six weeks, closing on 9 March 2026.

Baroness Amos is also meeting the senior team in each of the 12 trusts and staff panels are also being held on site.

A list of leaders for national organisations, including statutory, Arm’s Length Bodies, and the voluntary and charitable sector, is being developed by the National Maternity and Neonatal Investigation. Leaders of these organisations will be invited to a formal interview with the Chair, Director of investigation, and a member of the Expert Panel.

The National Maternity and Neonatal Investigation is also gathering evidence from organisations. Organisations and other individuals, for instance researchers, wishing to submit evidence to the investigation can submit this directly by email to the investigation mailbox. The deadline for all evidence submissions is 17 March 2026.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how often the national maternity and neonatal investigation team is engaging with professional bodies and organisations representing maternity and neonatal staff.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Following a meeting with West Mercia Police about the detail and schedule of their ongoing investigation, Baroness Amos concluded that the Shrewsbury and Telford Hospital NHS Trust should be removed from the National Maternity and Neonatal Investigation.

Leeds Teaching Hospitals NHS Trust was removed from the list of trusts under review as part of the national investigation following my Rt Hon. Friend, the Secretary of State for Health and Social Care’s decision to commission a separate independent maternity inquiry on 20 October.

The Call for Evidence for the National Maternity and Neonatal Investigation was launched in January 2026, and the investigation has encouraged families in Shrewsbury and Telford, and Leeds to participate.

On 26 January 2026, the Independent Maternity and Neonatal Investigation launched a Workforce Call for Evidence. This is open specifically to all those who work in the maternity and neonatal care pathway and is a separate to the public call for evidence. It takes the form of a short online survey and focuses on the experiences of staff delivering care across the maternity and neonatal pathway and how best to support teams to provide high-quality, safe, and compassionate care. Findings will inform the investigation’s national recommendations, due for publication in spring 2026.

Information about how to access the workforce survey has been distributed to all NHS trusts and the investigation is asking them to cascade the link to all maternity and neonatal staff groups. It is currently live and will be open for six weeks, closing on 9 March 2026.

Baroness Amos is also meeting the senior team in each of the 12 trusts and staff panels are also being held on site.

A list of leaders for national organisations, including statutory, Arm’s Length Bodies, and the voluntary and charitable sector, is being developed by the National Maternity and Neonatal Investigation. Leaders of these organisations will be invited to a formal interview with the Chair, Director of investigation, and a member of the Expert Panel.

The National Maternity and Neonatal Investigation is also gathering evidence from organisations. Organisations and other individuals, for instance researchers, wishing to submit evidence to the investigation can submit this directly by email to the investigation mailbox. The deadline for all evidence submissions is 17 March 2026.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, following the publication of the white paper A New Vision for Water, on 20 January, what plans they have to expand community water fluoridation to improve oral health outcomes in England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

A New Vision for Water sets out that public health will be considered in new water frameworks and regulations. This will support delivery of shared outcomes, like those in the 10-Year Health Plan, which commits to assessing the further rollout of water fluoridation in areas where oral health outcomes are worst. We will also expand community water fluoridation in the north east of England from 2028 so that it reaches 1.6 million more people by April 2030. We will also refurbish older, existing water fluoridation schemes in England, benefitting a further six million people by 2030.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to address inequalities in maternal health outcomes, particularly among women from deprived or marginalised backgrounds.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises that there are stark inequalities for women and babies, and that they should receive the high-quality care they deserve, regardless of their background, location, or ethnicity.

Baroness Amos is chairing the National Independent Maternity and Neonatal Investigation which aims to identify the drivers and impact of inequalities faced by women, babies, and families from Black and Asian backgrounds, as well as deprived and marginalised groups.

The Government is committed to setting an explicit target to close the maternal mortality gap. We are ensuring that we take an evidence-based approach to determining what targets are set, and that any targets set are women and baby-centred.

NHS England’s Perinatal Equity and Anti-Discrimination Programme aims to ensure that all service users and their families receive care that is free from discrimination and racism. Local Maternity and Neonatal Systems have published Equity and Equality action plans containing evidence-based interventions to support women and families from ethnic minority backgrounds or economically deprived areas. NHS England also launched the Maternal Care Bundle that sets clear standards across all services, focused on the main causes of maternal death and harm. The Maternal Care Bundle is avaiable on the NHS.UK website. Women from Black and Asian backgrounds are more at risk of specific clinical conditions that are the leading causes of death. This bundle targets these conditions, and we expect a decline in deaths and harm.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they have issued indicative spending figures for 2026–27 to integrated care boards; and if so, whether they will publish those figures.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England is responsible for determining allocations of financial resources to integrated care boards (ICBs), informed by a target formula to determine the ‘fair share’ of total funding available for each ICB. NHS England published allocations for ICBs covering 2026/27 to 2028/29 in November 2025, with further information available at the following link:

https://www.england.nhs.uk/publication/allocation-of-resources-2026-27-to-2027-28/

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to implement a sustainable funding model for independent adult hospices.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

We have provided a £125 million capital funding boost for eligible adult, and children and young people’s, hospices in England to ensure they have the best physical environment for care.

The Government is developing a Palliative Care and End-of-Life Care Modern Service Framework (MSF) for England. We will consider contracting and commissioning arrangements as part of our MSF. We recognise that there is currently a mix of contracting models in the hospice sector. By supporting integrated care boards (ICBs) to commission more strategically, we can move away from grant and block contract models. In the long term, this will aid sustainability and help hospices’ ability to plan ahead.

Officials are working closely with a number of stakeholders from the hospice sector in the development of the MSF.

Additionally, the recently published Medium-Term Planning Guidance and the Model ICB Blueprint set out that ICBs should act as strategic commissioners with core functions including: understanding current and projected total service utilisation and costs; identifying underserved communities; assessing quality, performance, and productivity of existing provision; and significantly reducing avoidable unplanned hospital admissions.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what guidance her Department provides on the complaints and redress routes available to vulnerable patients who have concerns about the contractual terms of telecare services to which they are referred following hospital discharge.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

By law, all health and social care services must have a procedure for dealing efficiently with complaints, and anyone who has seen or experienced poor-quality care has the right to complain to the organisation that provided or paid for the care.

Telecare is not a mandatory service for local authorities, but many choose to provide a telecare service due to its benefits. Some local authorities will also fully or partially fund telecare for some individuals based on a financial assessment. Local authorities are responsible for the contractual terms of telecare services that they provide, therefore in the first instance an individual should consider making a complaint with the relevant local authority.

If an individual is not satisfied with the way a local authority has dealt with their complaint, they may escalate it to the Local Government and Social Care Ombudsman who can investigate individual concerns. The Local Government and Social Care Ombudsman is the independent complaints lead for adult social care and investigates complaints from those receiving social care.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve digital infrastructure and IT connectivity for community care in primary care settings.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

In 2026/27, and as per the Medium Term Planning Framework – delivering change together 2026/27 to 2028/29, all integrated care boards and community health services providers must identify and act on productivity opportunities, including ensuring teams have the digital tools and equipment they need to connect remotely to health systems and patients, and expanding point-of-care testing in the community.

Through the Community Health Services Data Plan (2024/25-2026/27), work is underway to improve the quality, relevance, and timeliness of community health service data and, in turn, improve the patient experience in community health services.

In addition, our 10-Year Health Plan will help put services at the heart of the community and expand digital tools to manage health, including through the Single Patient Record. It will give patients real control over a single, secure, and authoritative account of their data and enable more coordinated, personalised, and predictive care. It will improve clinical outcomes, make decision-making more informed, and speed up the delivery of care.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of Health Innovation Network Impact Report 2024–25, published on 18 September 2025, in relation to the use of point-of-care diagnostic testing technologies for cardiovascular disease prevention in the NHS.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government welcomes the Health Innovation Network (HIN) Impact Report 2024/25, and the network's focus on cardiovascular disease as a strategic priority. We recognise the significant impact of the HINs in driving innovation into the National Health Service, benefitting 4.9 million patients and leveraging £3 billion of investment since 2018. This is why the Government’s 10-Year Health Plan and the Life Sciences Sector Plan make explicit commitments to continue funding and empowering them.

As set out in the 10-Year Health Plan, to accelerate progress on the ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework later this year.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Joint Committee on Vaccination and Immunisation’s (JCVI’s) advice in November 2024 to expand eligibility for the shingles vaccination programme to include people aged 80 and over, what assessment they have made of the impact of delays in implementation on those with comorbidities who are at highest risk of severe shingles disease; what steps they are taking to prioritise protection for these high-risk individuals; and whether they will commit to implementing the JCVI advice before this winter.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Currently, adults become eligible for their shingles vaccination when they turn 65 or 70 years of age, and they remain eligible until their 79th birthday. Adults who are severely immunosuppressed, and therefore most at risk of serious illness and complications from shingles, are eligible from 18 years old and do not have an upper age limit.

The shingles vaccination programme has been in place since 2013, and therefore there will be a significant portion of adults currently aged 80 years old and over who were offered, and received, Zostavax, the previous shingles vaccine. All those who were born after 1 September 1933 would have been offered a vaccine in the programme.

In November 2024, the Joint Committee on Vaccination and Immunisation provided advice to the Government on eligibility for the shingles vaccination programme. This included advice that the Government should consider expanding the shingles vaccination offer to include older adult cohorts aged 80 years old and over. The Government is carefully considering this advice as it sets the policy on who should be offered shingles vaccinations in the future.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what support they are giving to clinicians to provide a standardised approach to effective interventions for treatment of cardiovascular disease conditions.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

As set out in the 10-Year Health Plan, to accelerate progress on the ambition to reduce premature deaths from heart disease and stroke by 25% within a decade, we will publish a new cardiovascular disease modern service framework (CVD MSF) later this year.

The Department and NHS England are engaging widely with stakeholders to co-produce the CVD MSF, ensuring that experts, people, and communities are at the heart of its development. These frameworks will identify the best evidenced interventions that would support progress towards this goal, with a focus on those with the best means to drive up value and equity. Furthermore, they will set standards on how those interventions should be used, alongside a clear strategy to support and oversee uptake by clinicians and providers.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what consideration they are giving to appointing a National Cardiovascular Disease Director.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England has a National Clinical Director for Cardiovascular Disease (CVD) Prevention.

We are committed to reducing premature mortality from heart disease and stroke by 25% in the next ten years and are prioritising ambitious, evidence-led and clinically informed approaches to CVD prevention and care to tackle one of the country’s biggest killers head-on.

To accelerate progress towards this ambition, we will publish a CVD Modern Service Framework (CVD MSF) later this year. The framework will support consistent, high quality and equitable care whist fostering innovation across the CVD pathway. The Department and NHS England are engaging widely with stakeholders to co-produce the CVD MSF, ensuring that experts, people and communities are at the heart of its development.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that eligible women take up breast cancer screening in Sutton Coldfield constituency.

Answered by Ashley Dalton

Through our National Health Service screening programmes, we can reduce mortality and morbidity from cancer in the population who appear healthy and have no symptoms, by detecting conditions at an earlier, more treatable stage. Each year, over 15 million people are invited for screening, with over 10 million taking up the invitation.

In Birmingham and Solihull, between 2022/23 and 2023/24 there has been an improvement of 4.93% in breast cancer screening uptake in 53 to 70 year old people.

In Sutton Coldfield, the breast screening is offered to all eligible cohorts in line with service specifications of the NHS Breast Screening Programme. In this constituency, uptake and coverage are stable and constituents can access screening at both static and mobile facilities. There is a dedicated focus on reducing health inequalities, supporting access, and informing eligible patients to actively take up their screening appointment and offer.

The breast screening service in Sutton Coldfield is currently undertaking a targeted text messaging initiative targeting eligible patients that have not attended their screening invitation. This includes the offer to rebook their screening appointment and a link to bilingual breast screening videos to support education and awareness. A follow-up text message survey is also being used to explore barriers to attendance and motivating factors, with insights informing ongoing service development.

Other initiatives to increase uptake in the area include:

• a dedicated general practice toolkit to support and inform health promotion messaging;

• a breast screening resource pack for care homes to support staff in promoting screening awareness and facilitating uptake amongst eligible residents; and

• a cancer bus initiative promoting a range of services including breast cancer screening.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of support available to low‑income families whose children require prolonged inpatient neonatal and paediatric care.

Answered by Ashley Dalton

The Government is committed to tackling child poverty and to raising the healthiest generation of children ever. Our Children, Our Future: Tackling Child Poverty was published on 5 December 2025 and set out a goal to reduce and alleviate the impact of child poverty, with urgent action to improve the lives of children in deepest poverty.

We recognise the significant financial and practical pressures faced by low-income families when a child with a long-term condition requires hospital care. To support eligible low-income families with the costs associated with repeated or prolonged hospital stays, the NHS Healthcare Travel Costs Scheme provides support with the cost of travelling to hospital appointments.

In addition, many hospitals work with charitable partners, such as Ronald McDonald House Charities, to provide free or low-cost accommodation close to specialist children’s hospitals, helping parents stay near their child during treatment.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 17 November 2025 to Question 86092, how many claimants were awarded a payment under the Vaccine Damage Payments Scheme in each financial year since 2021-22.

Answered by Ashley Dalton

The NHS Business Services Authority is the administrator of the Vaccine Damage Payment Scheme (VDPS). The following table shows the total number of awarded claims in each financial year since 2021/22:

Note: Data for 2025/26 figure is accurate as of 6 February 2026. The previous question, answered on 28 October 2025, covered the period up until 30 September 2025. Some claims may be paid in a different financial year to which they were awarded.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what recent steps he has taken to help reduce rates of obesity in Slough.

Answered by Ashley Dalton

As set out in the 10-Year Health Plan for England, we are taking decisive action on the obesity crisis to shift the focus from treatment to prevention and ease the strain on our National Health Service, including in Slough.

We have fulfilled our commitment to restrict junk food advertising targeted at children on television and online. We have also implemented restrictions on volume price promotions for less healthy food and drink, such as three for the price of two offers, and consulted on our proposals to ban the sale of high-caffeine energy drinks to children aged under 16 years old.

We will go further by introducing mandatory reporting on the healthiness of sales for all large food businesses and setting new healthier food targets. We will also strengthen the existing advertising and promotions restrictions by applying an updated definition of ‘less healthy food and drink’. We published the updated Nutrient Profiling Model in January, ahead of consulting on its policy application.

To support people already living with obesity, we will double the number of patients able to access the NHS Digital Weight Management Programme. From June 2025, the NHS began making weight loss drugs available through primary care. Approximately 220,000 adults will be considered in the first three years with access prioritised by clinical need. We are committed to expanding NHS access and will work closely with industry and local systems to identify innovative ways to do this.

Officials in the Office for Health Improvement and Disparities’ South East team work closely with local partners including local authorities and the NHS to support them with local initiatives to promote a healthy lifestyle and to tackle obesity.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to HCWS1271 on Improving Cancer Care and Early Diagnosis, when bowel cancer screening invitations will be issued via the NHS App; what proportion of eligible patients currently use the App; what steps he is taking to help ensure that digitally excluded groups will continue to be supported; what assessment he has made of the adequacy of the trend in the levels of uptake in digital screening; and what safeguards exist to help ensure no eligible patients miss screening invitations.

Answered by Ashley Dalton

Whilst there is an increasing move towards digital National Health Service communications, NHS letters remain crucial for many patients, particularly those who may be digitally excluded, therefore, they will always be included in the screening offer. For bowel screening, NHS England currently uses NHS Notify which sends pre-invitations via the NHS App first, and if that message isn't read or the person doesn't have the app, a paper letter is sent. Everyone will still get sent a bowel cancer screening home testing kit through the post after pre-information, with information on completing the kit.

National roll out of digital pre-invitations is planned over the next couple of months, following a regional pilot last year. From that pilot, NHS England saw approximately 30% of people receive these communications via the NHS app. Based on other similar services, NHS England expects this to increase when other digital communications such as SMS are introduced.

National rollout has already been completed in cervical screening with positive results, where approximately 90% of invites are received via the NHS App or SMS.

Impact on the uptake of screening will be monitored over at least a six-month period to allow people time to take up their screening offer. To date, no negative impact has been indicated, but NHS England is monitoring closely to assess.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that the expansion of diagnostic genomic testing for cancer is accompanied by timely NHS access to targeted therapies identified by that testing, including where such therapies are not routinely commissioned.

Answered by Ashley Dalton

The National Cancer Plan, published on 4 February 2026, sets out clear actions to expand diagnostic genomic testing and ensure that this is matched by access to targeted therapies. The plan confirms that every cancer patient who would benefit from genomic testing, including those with rare cancers, will receive it within a clinically relevant timeframe.

To support timely access to treatments identified through genomic testing, a new joint National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency process from April 2026 will accelerate licensing and appraisal so that National Health Service funding recommendations can be made more quickly. The expansion of the NHS Genomic Medicine Service will also help identify suitable targeted therapies, connect patients to clinical trials faster, and integrate genomic data into the Single Patient Record by 2028.

With reference to page 75 of the National Cancer Plan, it is Government policy that patients with rare cancers should benefit from personalised and targeted therapies where genomic testing identifies a suitable option. The plan also strengthens specialist multidisciplinary teams for rare cancers so that patients can access expertise from specialist centres and the most up‑to‑date evidence‑based treatments.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to introduce a form of licencing for high street vape shops.

Answered by Ashley Dalton

The Tobacco and Vapes Bill, currently being considered in the House of Lords, provides powers for ministers in England, Wales, and Northern Ireland to introduce a licensing scheme, in their respective nations, for the retail sale of tobacco, vapes, and nicotine products. This will strengthen enforcement and support legitimate businesses, while acting as a deterrent to retailers who breach the law. In doing so, it will support public health.

We recently launched a call for evidence to gather views on a range of topics related to tobacco, vapes, and nicotine products, including the proposed licensing scheme. The call for evidence ran for eight weeks and closed in December 2025. The evidence gathered will be used to inform the development of the licensing scheme, and we will launch a subsequent consultation on our policy proposals before bringing forward secondary legislation.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to HCWS1271, what metrics his Department uses to measure geographic inequalities in cancer diagnosis, treatment and survival; which regions perform worst on early diagnosis and cancer outcomes; whether he will bring forward interventions to targeted the worst performing areas; and how his Department monitors and reports steps it is taking to help reduce such geographic disparities.

Answered by Ashley Dalton

The Department monitors geographic inequalities in cancer diagnosis and treatment through the NHS Cancer Waiting Time Standards, for which data is published at integrated care board and provider level. The NHS England Acute Provider Table for all 134 providers supports this transparency.

Early diagnosis is monitored through NHS England’s annual publication of early diagnosis data in England, the Case-mix Adjusted Percentage of Cancers Diagnosed at Stages 1 and 2. Early diagnosis data is published for England as a whole and for the integrated care boards. Survival data is monitored through NHS England's annual publication of cancer survival data in England. Cancer survival data is published for England as a whole, for the National Health Service regions, integrated care boards, and Cancer Alliances for 21 selected cancers. The index of cancer survival for all cancers is published for England, integrated care boards, and Cancer Alliances.

The Department recognises that outcomes remain poorest in some deprived, rural and coastal areas, where rates of early diagnosis and cancer survival are lower. To support improvement, the Government has provided £200 million of ring‑fenced funding for Cancer Alliances in 2026/27 to help the lowest‑performing trusts strengthen diagnostic pathways and reduce delays.

The Department monitors progress through regular oversight with NHS England, tracking improvements in early diagnosis and treatment standards across regions. These measures underpin our commitment to reducing geographic disparities so that a patient’s chances of survival do not depend on where they live.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if he will make an assessment of the provision of NHS treatment for Functional Neurological Disorder; and what steps he will take to resolve the disparities that currently exist between regions for the treatment of this condition.

Answered by Ashley Dalton

NHS England’s updated Specialised Neurology Service Specification, published in August 2025, includes specific reference to functional neurological disorder (FND). It states that all specialised neurology centres must include access to treatment services for FND. The updated Specialised Neurology Service Specification is available at the following link:

https://www.england.nhs.uk/publication/specialised-neurology-services-adults/

There are a number of other national-level initiatives supporting service improvement and better care for patients with neurological conditions, including FND, such as the Getting It Right First Time Programme for Neurology and the Neurology Transformation Programme, which aim to improve care for people by reducing variation and delivering care more equitably across England.

Additionally, we have set up a UK Neuro Forum facilitating formal, which are twice-yearly meetings across the Department, NHS England, the devolved administrations and health services, and the Neurological Alliances of all four nations. The new forum brings key stakeholders together, to share learning across the system and to discuss challenges, best practice examples, and potential solutions for improving the care of people with neurological conditions, including FND.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to page 75 of the policy paper entitled A National Cancer Plan for England: delivering world class cancer care, whether it is his policy that patients with rare cancers should be offered targeted and personalised therapies where genomic testing identifies a suitable potential treatment.

Answered by Ashley Dalton

The National Cancer Plan, published on 4 February 2026, sets out clear actions to expand diagnostic genomic testing and ensure that this is matched by access to targeted therapies. The plan confirms that every cancer patient who would benefit from genomic testing, including those with rare cancers, will receive it within a clinically relevant timeframe.

To support timely access to treatments identified through genomic testing, a new joint National Institute for Health and Care Excellence and Medicines and Healthcare products Regulatory Agency process from April 2026 will accelerate licensing and appraisal so that National Health Service funding recommendations can be made more quickly. The expansion of the NHS Genomic Medicine Service will also help identify suitable targeted therapies, connect patients to clinical trials faster, and integrate genomic data into the Single Patient Record by 2028.

With reference to page 75 of the National Cancer Plan, it is Government policy that patients with rare cancers should benefit from personalised and targeted therapies where genomic testing identifies a suitable option. The plan also strengthens specialist multidisciplinary teams for rare cancers so that patients can access expertise from specialist centres and the most up‑to‑date evidence‑based treatments.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the National Cancer Plan, what steps his Department is taking to help ensure that there will be enough pathologists to support the Plan’s delivery.

Answered by Ashley Dalton

The National Cancer Plan sets out how we will strengthen the cancer workforce, including for diagnostics, such as pathology. The plan sets out sustainable workforce growth, focused not on simply expanding numbers but on ensuring staff are properly trained, supported, and able to work at the top of their skills.

The plan sets out how we will support pathologists to work more efficiently through a £604 million investment in digital diagnostics, including digital pathology, and £96 million in the automation of histopathology, as well as further investment in digital technology and artificial intelligence. Expansion of advanced clinical practice for scientists will also improve the efficiency and effectiveness of the pathology workforce as a whole.

The 10 Year Workforce Plan will be published in spring, setting out further action to create a workforce able to deliver the transformed service set out in the 10-Year Health Plan.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the economic and societal costs of maintaining a health technology assessment framework for vaccines that does not explicitly account for wider impacts beyond the health system, including potential losses to productivity.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises the value in improving our understanding of the impact that vaccines have on wider society. Demonstrating the impact that childhood vaccines can have on the number of days of education that children may miss, for example, could encourage greater uptake of childhood vaccination. We have recently been able to say that childhood chickenpox costs the United Kingdom’s economy £24 million every year in lost income and productivity, and the chickenpox vaccination programme launched last month is expected to reduce that loss.

Vaccine appraisals play a particular role within the process of understanding that value, using the best robust evidence available across all vaccination programmes to focus investment of the health budget on programmes that deliver the greatest health benefit to the greatest number of people. Focusing our appraisal process on health benefits and costs, which have better evidence than socio-economic impacts, follows the process used by the National Institute for Health and Care Excellence.

If this process were to change, and wider socio-economic benefits were to be formally included, this could have unintended consequences. For example, it could have the effect of prioritising investment in vaccines for working populations over those who are not or will not be economically active. Additionally, the available data on socio-economic benefits is robust for only a small number of vaccines. Factoring this data into appraisals for only a small number of vaccines would create a bias for these programmes with better quality data. Conversely, if this data on wider benefits were to be factored into appraisals for all vaccination programmes, the use of lower quality data risks increasing uncertainty in appraisals and reduces our ability to ensure responsible and effective spending of public funds.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what evidence, analysis or expert advice Ministers relied on in concluding that broadening the scope of health technology assessments for vaccines to include wider economic and societal impacts is unnecessary; and whether this conclusion was informed by any assessment of the capability and remit of the National Institute of Health and Clinical Excellence and the Joint Committee on Vaccination and Immunisation in areas beyond pure health system cost-effectiveness, such as macro-economics, public finance, and social and welfare analysis.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

We are proud to have one of the most comprehensive vaccination programmes in the world. Our approach to evaluating vaccination programmes, underpinned by recommendations and advice from the Joint Committee on Vaccination and Immunisation (JCVI), is grounded in rigorous and evidence-led cost-effectiveness analysis, and ensures that decisions are objective, consistent, and based on high-quality data on health benefits and costs.

Basing our approach on these factors avoids the uncertainty of less direct benefits, where the evidence and therefore the decision is likely to be less defensible. This approach is also informed by previous work on this topic.

For example, earlier work by the independent Cost-Effectiveness Methodology for Immunisation Programmes and Procurement (CEMIPP) considered, amongst other things, whether wider socio-economic impacts should be included in the framework used to assess the cost-effectiveness of vaccines. CEMIPP conducted a consultation as part of their wider work and drew upon a broad body of expert opinion. The group concluded that wider socio-economic impacts should not be included in vaccine cost-effectiveness assessments unless doing so becomes standard practice across all health technology assessments.

Additionally, in 2022, the National Institute for Health and Care Excellence (NICE) undertook a detailed appraisal of whether it should broaden the perspective it uses in its economic evaluations, including consideration of wider societal impacts. Following this review, and after examining both international comparisons, and the significant methodological and ethical challenges involved, NICE’s Board concluded that it should retain its current approach of using a health-sector perspective routinely, but with the flexibility to include wider societal benefits when they are especially relevant.

Whilst the expertise of the JCVI rightly centres on disease burden, vaccine efficacy, health outcomes and health-related costs, as outlined this is not a key reason for why the cost-effectiveness methodology for vaccines does not formally take into consideration wider socio-economic benefits.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what steps they are taking to strengthen the evidence base for assessing the wider economic and societal impacts of vaccination; and what assessment they have made of the potential benefits for evidence generation of explicitly incorporating such impacts into health technology assessment frameworks.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises the value in improving our understanding of the impact that vaccines have on wider society. Demonstrating the impact that childhood vaccines can have on the number of days of education that children may miss, for example, could encourage greater uptake of childhood vaccination. We have recently been able to say that childhood chickenpox costs the United Kingdom’s economy £24 million every year in lost income and productivity, and the chickenpox vaccination programme launched last month is expected to reduce that loss.

Vaccine appraisals play a particular role within the process of understanding that value, using the best robust evidence available across all vaccination programmes to focus investment of the health budget on programmes that deliver the greatest health benefit to the greatest number of people. Focusing our appraisal process on health benefits and costs, which have better evidence than socio-economic impacts, follows the process used by the National Institute for Health and Care Excellence.

If this process were to change, and wider socio-economic benefits were to be formally included, this could have unintended consequences. For example, it could have the effect of prioritising investment in vaccines for working populations over those who are not or will not be economically active. Additionally, the available data on socio-economic benefits is robust for only a small number of vaccines. Factoring this data into appraisals for only a small number of vaccines would create a bias for these programmes with better quality data. Conversely, if this data on wider benefits were to be factored into appraisals for all vaccination programmes, the use of lower quality data risks increasing uncertainty in appraisals and reduces our ability to ensure responsible and effective spending of public funds.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the quantified economic and societal benefits omitted from vaccine appraisals under the existing health technology assessment framework, including impacts on economic inactivity, workforce participation, productivity and long-term growth.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises the value in improving our understanding of the impact that vaccines have on wider society. Demonstrating the impact that childhood vaccines can have on the number of days of education that children may miss, for example, could encourage greater uptake of childhood vaccination. We have recently been able to say that childhood chickenpox costs the United Kingdom’s economy £24 million every year in lost income and productivity, and the chickenpox vaccination programme launched last month is expected to reduce that loss.

Vaccine appraisals play a particular role within the process of understanding that value, using the best robust evidence available across all vaccination programmes to focus investment of the health budget on programmes that deliver the greatest health benefit to the greatest number of people. Focusing our appraisal process on health benefits and costs, which have better evidence than socio-economic impacts, follows the process used by the National Institute for Health and Care Excellence.

If this process were to change, and wider socio-economic benefits were to be formally included, this could have unintended consequences. For example, it could have the effect of prioritising investment in vaccines for working populations over those who are not or will not be economically active. Additionally, the available data on socio-economic benefits is robust for only a small number of vaccines. Factoring this data into appraisals for only a small number of vaccines would create a bias for these programmes with better quality data. Conversely, if this data on wider benefits were to be factored into appraisals for all vaccination programmes, the use of lower quality data risks increasing uncertainty in appraisals and reduces our ability to ensure responsible and effective spending of public funds.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the potential benefits of incorporating wider societal impacts into health technology assessments on the assessment of value for money and long term return on investment for vaccination programmes.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government recognises the value in improving our understanding of the impact that vaccines have on wider society. Demonstrating the impact that childhood vaccines can have on the number of days of education that children may miss, for example, could encourage greater uptake of childhood vaccination. We have recently been able to say that childhood chickenpox costs the United Kingdom’s economy £24 million every year in lost income and productivity, and the chickenpox vaccination programme launched last month is expected to reduce that loss.

Vaccine appraisals play a particular role within the process of understanding that value, using the best robust evidence available across all vaccination programmes to focus investment of the health budget on programmes that deliver the greatest health benefit to the greatest number of people. Focusing our appraisal process on health benefits and costs, which have better evidence than socio-economic impacts, follows the process used by the National Institute for Health and Care Excellence.

If this process were to change, and wider socio-economic benefits were to be formally included, this could have unintended consequences. For example, it could have the effect of prioritising investment in vaccines for working populations over those who are not or will not be economically active. Additionally, the available data on socio-economic benefits is robust for only a small number of vaccines. Factoring this data into appraisals for only a small number of vaccines would create a bias for these programmes with better quality data. Conversely, if this data on wider benefits were to be factored into appraisals for all vaccination programmes, the use of lower quality data risks increasing uncertainty in appraisals and reduces our ability to ensure responsible and effective spending of public funds.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what action they are taking to promote best practice in data collection and service standards for early identification and treatment of patients with cardiovascular disease.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Government is strengthening best practice in cardiovascular disease prevention through CVDPREVENT, a national primary care audit that enables general practices (GPs) and primary care networks (PCNs) to extract data held by GPs to identify gaps in diagnosis, and management of people who are at risk of cardiovascular disease. The aim is to improve patient care, reduce inequalities, and optimise treatment.

Furthermore, this year, we will publish a new cardiovascular disease modern service framework (CVD MSF). The Department and NHS England are engaging widely with stakeholders to co-produce the CVD MSF, ensuring that experts, people, and communities are at the heart of its development. The CVD MSF will support evidence-led, consistent, high quality and equitable care whilst fostering innovation across the cardiovascular disease pathway.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what provision the National Cancer Plan will make for orphan drug pathways for patients with rare cancers requiring personalised treatment plans; and how those pathways will differ from existing commissioning arrangements.

Answered by Ashley Dalton

On 4 February 2026, NHS England and the Department published a National Cancer Plan for England. The National Cancer Plan is part of our work to build a National Health Service that is fit for the future and will make England a world-leader for cancer survival.

The orphan drug designation is assessed by the Medicines and Healthcare products Regulatory Agency and is granted at the same time as the marketing authorisation. It provides a period of market exclusivity during which similar competitor medicines cannot enter the United Kingdom market. The orphan drug regulations are designed to support the development of medicines to treat rare diseases including rare cancers.

All new licensed medicines, including orphan medicines, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the NHS on whether they represent a clinically and cost-effective use of NHS resources. NICE aims wherever possible to issue recommendations on new medicines close to the time of licensing, and the NHS in England is legally required to fund medicines recommended by NICE. NICE has a strong track record in recommending orphan medicines for use on the NHS and many thousands of patients with rare diseases have benefitted from access to new medicines as a result.

The Rare Cancers Bill, currently going through the House of Lords, places a duty on the Government to publish a review of the law related to marketing authorisation for rare cancer drugs, for instance orphan drugs for cancer, comparing the UK’s approach to other approaches internationally. Through the National Cancer Plan the Government has committed to full implement of the Rare Cancers Bill to streamline trial pathways and review regulatory barriers that prevent access to promising new treatments.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what consideration has been given to the role of the generic and biosimilar medicines sector in shaping life sciences policy, in the context of it supplying around 85% of NHS prescription drugs by volume.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.

Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of poor air quality in (a) ambient air and (b) indoor air on different age groups of people in England.

Answered by Ashley Dalton

Poor air quality is a major public health risk in the United Kingdom. An estimated 29,000 to 43,000 deaths were attributable to long-term exposure to ambient air pollution in the UK in 2019 among adults aged 30 years old and over.

Indoor residential exposure to damp and mould was associated with approximately 5,000 cases of asthma and 8,500 lower respiratory infections among children, those who are aged between zero to 14 years old, and adults, those who are aged between 15 to 49 years old, in England in 2019.

The UK Health Security Agency (UKHSA) contributed to a report by the Royal College of Physicians in 2025. This contained data on new cases of mortality, myocardial infarction, asthma, lung cancer, and other conditions, attributable to a range of air pollutants in 2019 and predicted for 2040, among children, those over 30 years old, over 60 years old, and at all ages. The report is available at the following link:

https://www.rcp.ac.uk/policy-and-campaigns/policy-documents/a-breath-of-fresh-air-responding-to-the-health-challenges-of-modern-air-pollution/

The Department’s 10-Year Health Plan sets out how the Government will act to reduce the health harms of air pollution. This includes action to reduce harm from ambient air pollution and tackling poor indoor air by improving the standard of rented homes with relation to damp and mould.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of reinstating the Life Sciences Council with representation from the generic and biosimilar medicines industry.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.

Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when the Government plans to establish a task and finish group to oversee delivery of the Life Sciences Sector Plan as it relates to generic and biosimilar medicines.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. As set out in the Life Sciences Sector Plan, which we developed while working closely with the sector, there is an opportunity for the National Health Service to save £1 billion over five years through biosimilars uptake, delivering value for patients and the NHS. The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.

Medicines UK and its members are represented on the Single National Formulary Industry Task and Finish Group. In addition, the Government is working to convene further task and finish groups to drive forward defined areas of the Life Sciences Sector Plan, including in the generic and biosimilars space. These groups will direct focused ministerial and official attention toward a clear set of priorities and will work closely with industry to deliver tangible progress within a set timeframe.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he plans to reply to the email from the hon. Member for South Shropshire dated 24 October 2025 with case reference number SA36602.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department has received the Hon. Member’s letter and I will respond shortly.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to ensure that NHS organisations and contracted wheelchair service providers are subject to more rigorous, mandatory regulation.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchair services, based on the needs of their local population. NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services and to reduce delays in people receiving timely intervention and wheelchair equipment.

This includes publishing a Wheelchair Quality Framework on 9 April 2025, which sets out quality standards and statutory requirements for ICBs. The framework is available at the following link:

https://www.england.nhs.uk/long-read/wheelchair-quality-framework/

NHS England also introduced personal wheelchair budgets, including legal rights in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided.

Since July 2015, NHS England has collected quarterly data from ICBs on wheelchair provision, including waiting times, to enable targeted action if improvement is required. The latest figures from the Quarter 2 2025/26 National Wheelchair Data Collection showed that 84% of adults and 78% of children received their equipment within 18 weeks. Further information on the National Wheelchair Data Collection is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhse-national-wheelchair-data-collection/q2-2025-26

The Medium-Term Planning Framework sets a requirement for all providers and ICBs to actively manage long waits for community health services reducing the proportion of all waits over 18 weeks. This will be monitored via the NHS’s usual regional and national assurance processes.

The Community Health Services Situation Report, which will be used to monitor ICB performance against waiting time targets in 2026/27, currently monitors waiting times for both children and young people, and adult waiting times under the ‘Wheelchair, Orthotics, Prosthetics and Equipment’ line. These targets will guide systems to reduce the longest waits, and improvement initiatives to meet these targets may affect waits that are over 18-weeks and 52-weeks.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the adequacy of the performance of AJM Healthcare in delivering wheelchair services to the NHS.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The safety of all patients, whether they are treated in the National Health Service or the independent sector, is a top priority for the Government. There are a range of providers of NHS wheelchair services across England. Integrated care boards (ICBs) are responsible for monitoring service provision and effectively managing contracts with their commissioned providers.

NHS England are aware there have been a number of separate complaints about the quality of services provided by AJM Healthcare, which are being dealt with on an individual basis by the Ombudsman’s office. NHS England has flagged this to the relevant ICBs, who are responsible for the provision and commissioning of local wheelchair services. NHS England supports ICBs to make improvements and commission effective, efficient, and personalised wheelchair services. Actions taken include:

- establishing a national wheelchair dataset, where data has been collected quarterly from ICBs, formerly clinical commissioning groups, since July 2015 and which supports the drive for improvements in wheelchair services. This data looks at waiting times across the pathway to enable targeted action if improvement is required. Further information is available at the following link:
https://www.england.nhs.uk/statistics/statistical-work-areas/national-wheelchair/

- the Wheelchair Quality Framework, which was published on the 9 April 2025, and which was co-produced with key stakeholders, including Whizz Kids. The framework sets out quality standards and statutory requirements for ICBs, such as offering personal wheelchair budgets, with further information available at the following link:
https://www.england.nhs.uk/long-read/wheelchair-quality-framework/

- personal wheelchair budgets, with NHS England having introduced personal wheelchair budgets, including in legal rights, in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided, with further information available at the following link:
https://www.england.nhs.uk/publication/guidance-on-the-legal-rights-to-have-personal-health-budgets-and-personal-wheelchair-budgets/

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to help ensure that increased medicine prices do not have an adverse impact on NHS activity.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

This deal is a vital investment that builds on the strength of our National Health Service and world leading life sciences sector to increase access to life-changing medicines without taking essential funding from our frontline NHS services.

We will always prioritise the needs of NHS patients and at the Spending Review we delivered record real terms increase for day-to-day spending for the NHS in England up to April 2029.

This deal will be funded by allocations made at the Spending Review, where front line services will remain protected through the record funding secured. Future year funding will be settled at the next Spending Review.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that funding for wheelchair users is adequate to meet essential needs, including equipment and specialist support.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchair services, based on the needs of their local population. NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services and to reduce delays in people receiving timely intervention and wheelchair equipment.

This includes the introduction of personal wheelchair budgets, including through legal rights in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided.

NHS England also published a Wheelchair Quality Framework on 9 April 2025, which sets out quality standards and statutory requirements for ICBs. The framework is available at the following link:

https://www.england.nhs.uk/long-read/wheelchair-quality-framework/

Since July 2015, NHS England has collected quarterly data from ICBs on wheelchair provision, including waiting times, to enable targeted action if improvement is required. The latest figures from the Quarter 2 2025/26 National Wheelchair Data Collection showed that 84% of adults and 78% of children received their equipment within 18 weeks. Further information on the National Wheelchair Data Collection is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhse-national-wheelchair-data-collection/q2-2025-26

Local authorities in England have a statutory duty under various legislations, including the Care Act 2014, and the Children and Families Act 2014, to make arrangements for the provision of disability aids and community equipment, to meet the assessed eligible needs of individuals who are resident in their area. Some local authorities deliver this themselves, but a significant number have external contracts for an integrated community equipment service.

NHS England is also responsible for determining allocations of financial resources to ICBs. NHS England’s allocations policy aims to support equal opportunity of access for equal need, alongside NHS England’s duties to reduce health inequalities that are amenable to healthcare.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has marked 2025/26 as a financial reset year with the publication of Planning Guidance 2025/26. He has been clear that systems must live within their means, exhausting all opportunities to improve productivity, tackle waste, and take decisions on how to prioritise resources to best meet the health needs of their local population.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what statistics he has on the demand for and use of wheelchairs; and how that data informs NHS England’s commissioning of appropriate services.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchair services, based on the needs of their local population. NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services and to reduce delays in people receiving timely intervention and wheelchair equipment.

This includes the introduction of personal wheelchair budgets, including through legal rights in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided.

NHS England also published a Wheelchair Quality Framework on 9 April 2025, which sets out quality standards and statutory requirements for ICBs. The framework is available at the following link:

https://www.england.nhs.uk/long-read/wheelchair-quality-framework/

Since July 2015, NHS England has collected quarterly data from ICBs on wheelchair provision, including waiting times, to enable targeted action if improvement is required. The latest figures from the Quarter 2 2025/26 National Wheelchair Data Collection showed that 84% of adults and 78% of children received their equipment within 18 weeks. Further information on the National Wheelchair Data Collection is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhse-national-wheelchair-data-collection/q2-2025-26

Local authorities in England have a statutory duty under various legislations, including the Care Act 2014, and the Children and Families Act 2014, to make arrangements for the provision of disability aids and community equipment, to meet the assessed eligible needs of individuals who are resident in their area. Some local authorities deliver this themselves, but a significant number have external contracts for an integrated community equipment service.

NHS England is also responsible for determining allocations of financial resources to ICBs. NHS England’s allocations policy aims to support equal opportunity of access for equal need, alongside NHS England’s duties to reduce health inequalities that are amenable to healthcare.

My Rt Hon. Friend, the Secretary of State for Health and Social Care, has marked 2025/26 as a financial reset year with the publication of Planning Guidance 2025/26. He has been clear that systems must live within their means, exhausting all opportunities to improve productivity, tackle waste, and take decisions on how to prioritise resources to best meet the health needs of their local population.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to make the recently developed service specification guidelines for wheelchair services mandatory across England.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Integrated care boards (ICBs) are responsible for the provision and commissioning of local wheelchair services, based on the needs of their local population. NHS England supports ICBs to commission effective, efficient, and personalised wheelchair services and to reduce delays in people receiving timely intervention and wheelchair equipment.

This includes publishing a Wheelchair Quality Framework on 9 April 2025, which sets out quality standards and statutory requirements for ICBs. The framework is available at the following link:

https://www.england.nhs.uk/long-read/wheelchair-quality-framework/

NHS England also introduced personal wheelchair budgets, including legal rights in 2019, providing a clear framework for ICBs to commission personalised wheelchair services which are outcomes focused and integrated. Personal wheelchair budgets give people greater choice over the wheelchair provided.

Since July 2015, NHS England has collected quarterly data from ICBs on wheelchair provision, including waiting times, to enable targeted action if improvement is required. The latest figures from the Quarter 2 2025/26 National Wheelchair Data Collection showed that 84% of adults and 78% of children received their equipment within 18 weeks. Further information on the National Wheelchair Data Collection is available at the following link:

https://digital.nhs.uk/data-and-information/publications/statistical/nhse-national-wheelchair-data-collection/q2-2025-26

The Medium-Term Planning Framework sets a requirement for all providers and ICBs to actively manage long waits for community health services reducing the proportion of all waits over 18 weeks. This will be monitored via the NHS’s usual regional and national assurance processes.

The Community Health Services Situation Report, which will be used to monitor ICB performance against waiting time targets in 2026/27, currently monitors waiting times for both children and young people, and adult waiting times under the ‘Wheelchair, Orthotics, Prosthetics and Equipment’ line. These targets will guide systems to reduce the longest waits, and improvement initiatives to meet these targets may affect waits that are over 18-weeks and 52-weeks.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how lipoedema is classified within NICE guidance and NHS commissioning frameworks; and whether he plans to review the categorisation of lipoedema-related interventions to ensure they reflect clinical need.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Lipoedema services in England are commissioned locally by integrated care boards (ICBs), which are responsible for assessing the needs of their local populations and determining the most appropriate services to support people with long‑term conditions such as lipoedema.

There is no single national specification for lipoedema services. Instead, ICBs draw on a range of national guidance and best‑practice resources when designing care pathways. These include guidance from the National Institute for Health and Care Excellence (NICE) and best‑practice frameworks produced by bodies such as Wounds UK and the Royal College of General Practitioners. This helps ensure that services are safe, effective, and based on the best available evidence.

Most people with lipoedema are supported through primary and community care services, including assessment by local lymphoedema teams, compression therapy, advice on skin care and movement, and support with self‑management. These services aim to help people manage symptoms and maintain mobility and quality of life.

NICE classifies lipoedema within its interventional procedures guidance on the use of liposuction for chronic lipoedema, reference code HTG618, as a chronic, often painful, and progressive condition characterised by the abnormal, symmetrical accumulation of fat in the legs, hips, buttocks, and sometimes arms. In this guidance, NICE concluded that current evidence on both safety and effectiveness is limited and, therefore, recommends that liposuction should only be undertaken within the context of research or under rigorous governance arrangements. This guidance informs, but does not mandate, local commissioning decisions. NICE will review this guidance once the full results of the ongoing LIPLEG clinical trial are available, and will update its recommendations if new evidence supports doing so.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what progress the MRS has made in delivering mechanistic research into ME/CFS.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

We do not know what ‘MRS’ refers to in this context. The Department funds research through the National Institute for Health and Care Research (NIHR). A limited amount of mechanistic research is funded through the NIHR, but the majority of mechanistic research is funded through the Medical Research Council (MRC), a UK Research and Innovation Council sponsored by the Department for Science, Innovation and Technology. Mechanistic research into myalgic encephalomyelitis, also known as chronic fatigue syndrome, is within the remit of the MRC.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, in response to Question tabled on 15 December 2025, UIN 99871, if the Government can outline what steps are being taken to ensure the needs of people with severe Myalgic Encephalomyelitis are adequacy met.

Answered by Ashley Dalton

The final delivery plan on myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), published in July 2025, includes an action for the Department and NHS England to explore whether a specialised service should be prescribed by my Rt. Hon. Friend, the Secretary of State for Health and Social Care, for severe ME/CFS. Officials from the Department have commenced discussions with NHS England on how best to take forward this action.

The third and final session in NHS England’s newly-developed ME/CFS e-learning series, Managing Severe ME/CFS, is now live on the NHS Learning Hub. This session provides practical, evidence-based guidance for healthcare professionals to support people living with severe and very severe ME/CFS.

Additionally, as set out in the Plan for Change, we are committed to returning to the NHS constitutional standard that 92% of patients wait no longer than 18 weeks from referral to consultant-led treatment by March 2029. We exceeded our pledge to deliver an extra two million appointments, tests, and operations in our first year of government, having delivered 5.2 million additional appointments between July 2024 and June 2025. This will help people with severe ME/CFS to get support sooner.

The 10-Year Health Plan sets out a transformed vision for elective care by 2035, where most interactions no longer take place in a hospital building, instead happening virtually or via neighbourhood services. We will empower patients by giving them greater choice and control and establishing expected standards for making their experience of planned NHS care as smooth, supportive and convenient as possible, including for people with severe ME/CFS.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps is the Department taking to remove barriers preventing community homelessness health services, such as mobile clinics, from accessing NHS SystemOne records.

Answered by Ashley Dalton

It is important that community health teams can access the information they need to provide quality care, including for people who are experiencing homelessness. NHS England and the Phoenix Partnership (TPP), the company that provides SystemOne, already offer several routes for some clinicians to view records outside of GP settings.

These include national services such as GP Connect and the National Care Records Service (NCRS), which allow clinicians to see key information from GP records. NCRS can also be used on mobile devices such as iPads. Integrated care systems are rolling out Shared Care Records, which give clinicians wider access to both GP and secondary care records, where appropriate.

More broadly, the Government’s commitments to improve health outcomes for people experiencing homelessness are set out in the cross-government strategy, A National Plan to End Homelessness. Through this strategy, we are working with NHS England, local authorities, and third sector partners to strengthen integrated care pathways. This includes improving collaboration between primary care, outreach teams, and community services. More information about the strategy is available at the following link:

https://www.gov.uk/government/publications/a-national-plan-to-end-homelessness/a-national-plan-to-end-homelessness

The Single Patient Record will enable improvements as it will provide a comprehensive view of health and care information across care settings. It will give both patients and professionals secure access to a single, accurate and up-to-date record – wherever and whenever it's needed.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans his Department has to publish updated guidance on managing conflicts of interest between civil servants and Ministers in relation to unhealthy commodity industries.

Answered by Ashley Dalton

The Department already has established arrangements in place to manage conflicts of interest for both ministers and civil servants, including where these relate to engagement with representatives of unhealthy commodity industries.

Ministerial conduct is governed by the Ministerial Code, which sets out requirements on the declaration and handling of ministers’ interests. Civil servants are bound by the Civil Service Code, and by departmental policies that set out how actual, potential, or perceived conflicts of interest must be identified, declared, and managed.

The Department keeps its internal guidance under regular review to ensure it remains aligned with cross-Government standards and supports transparent and accountable decision-making.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to manage conflicts of interest associated with alcohol industry involvement in public health policy.

Answered by Ashley Dalton

The Department already has established arrangements in place to manage conflicts of interest for both ministers and civil servants, including where these relate to the alcohol industry.

Ministerial conduct is governed by the Ministerial Code, which sets out requirements on the declaration and handling of ministers’ interests. Civil servants are bound by the Civil Service Code, and by departmental policies that set out how actual, potential, or perceived conflicts of interest must be identified, declared, and managed.

The Department keeps its internal guidance under regular review to ensure it remains aligned with cross-Government standards and supports transparent and accountable decision-making.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how many yellow card reports of Post 5-Alpha Reductase Inhibitor Syndrome the Medicines and Healthcare products Regulatory Agency has received each year since 2019; and what medications those reports were tied to.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Medicines and Healthcare products Regulatory Agency (MHRA) is responsible for ensuring that medicines, medical devices, and blood components for transfusion meet applicable standards of safety, quality, and efficacy. The MHRA rigorously assesses available data, including from the Yellow Card scheme, and seeks advice from the Commission on Human Medicines, the MHRA’s independent advisory committee, where appropriate, to inform regulatory decisions including amending the product information.

The MHRA has received a total of four United Kingdom reports through the Yellow Card scheme associated with the reaction term Post 5-Alpha Reductase Inhibitor Syndrome from 1 January 2019 up to and including 4 February 2026. The following table shows a yearly breakdown of reports associated with Post 5-Alpha Reductase Inhibitor Syndrome:

In addition, the following table shows a yearly breakdown of reports received by substance associated with Post 5-Alpha Reductase Inhibitor Syndrome:

Please note that each report may list more than one suspect drug. Therefore, the total number of reports received cannot be accurately derived from the figures presented in the above table.

It is important to note that anyone can report to the MHRA’s Yellow Card scheme and the recording of these reports in the Yellow Card database does not necessarily mean that the adverse reactions have been caused by the suspect drug. Many factors must be considered in assessing causal relationships, including temporal association, the possible contribution of concomitant medication, and the underlying disease. We encourage reporters to report suspected adverse reaction reports, as the reporter does not have to be sure of a causal association between the drug and the reactions, a suspicion will suffice.

The number of reports received cannot be used as a basis for determining the incidence of a reaction, as neither the total number of reactions occurring, nor the number of patients using the drug, is known.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they will involve an organisation representative from the children and young people's sector in the delivery of the plans for children and young people in the National Cancer Plan for England.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The National Cancer Plan, published on 4 February 2026, will ensure that young cancer patients and their families receive better support, across diagnosis, treatment, and patient experience.

The Department has worked closely with the Children and Young People (CYP) Cancer Taskforce, to develop ambitious commitments on CYP cancer in the National Cancer Plan. The taskforce brought together experts across a range of fields to identify ways to improve outcomes and patient experience for young cancer patients and has been committed to ensuring the voices of key charity stakeholders and patients are included.

That’s why the Government assembled a Charity Sub-Group and Patient Experience Panel to ensure this expertise fed directly into the work of the taskforce.

The Government is committed to continuing its work with key cancer partners to deliver the commitments outlined in the National Cancer Plan.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 30 January (HL13777), when they will publish the results of the consultation on proposals to extend the medicines responsibilities of four professions.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The consultation for proposals to extend medicines responsibilities for paramedics, physiotherapists, operating department practitioners, and diagnostic radiographers closed on 28 October 2025. Our team is currently analysing the large number of respondents received and a Government response detailing next steps will be published in due course.

Non-medical prescribing remains a keen area of interest since the Government took office in 2024, and we support the expansion of professional groups being able to use legal mechanisms to supply, administer, and prescribe medicines to patients, where it is safe to do so, within their scope of practice.

Question to the Department of Health and Social Care:

To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 29 January (HL13801), whether they plan to collect data on respiratory syncytial virus related hospital admissions of infants under one year old in weekly surveillance reports; if not, for what reason this data is being omitted.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

Numbers of respiratory syncytial virus (RSV) admissions in infants are reported by a sentinel network of approximately 15 to 20 National Health Service trusts in England to the Severe Acute Respiratory Infections-Watch Surveillance at the UK Health Security Agency. Participation in this surveillance is completely voluntary for NHS trusts. Therefore, the number of participating trusts can vary from week to week, and comparisons based on simple counts may be misleading.

To provide appropriate context for reported weekly data, weekly admission rates are calculated to monitor trends over time. This uses trust catchment populations published by the Office for Health Improvement and Disparities, which are estimated for under five-year-olds, but which have not been estimated specifically for the under one year old age group, or infants.

Therefore, published rates are based on the available denominator data for the under five-year-olds, and these are publicly available in the national surveillance weekly reports and corresponding datafile at the GOV.UK website.

Further surveillance data and a programme impact assessment will be included in the annual surveillance report on RSV, due to be published in summer 2026. Please refer to the 2024/25 annual surveillance report for a summary of the previous winter season, which is available at the GOV.UK website.

Surveillance reports use hospital admission data and the Office for National Statistics’ mid-year estimates to model catchment populations for hospital trusts. Modelled catchment populations use hospital data, aggregated over three years and resident populations in five-year age bands.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they plan to work with Young Lives vs Cancer to deliver the travel fund for young cancer patients.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department knows that the cost of travel is an important issue for many young cancer patients and their families across the United Kingdom.

Through the National Cancer Plan, the Government is committing up to £10 million a year to a new fund open to all children and young people in England with cancer and their families regardless of income, to support them with the cost of travelling to and from treatment. This commitment sits alongside wider action to transform cancer care for children and young people.

The Department has worked closely with the Children and Young People (CYP) Cancer Taskforce, to develop ambitious commitments on CYP cancer in the National Cancer Plan. The taskforce brought together experts across a range of fields to identify ways to improve outcomes and patient experience for young cancer patients and has been committed to ensuring the voices of key charity stakeholders and patients are included.

That’s why the Government assembled a Charity Sub-Group and Patient Experience Panel to ensure this expertise fed directly into the work of the taskforce.

The Government is committed to continuing its work with key cancer partners, including Young Lives vs Cancer, to deliver the commitments outlined in the National Cancer Plan.

Question to the Department of Health and Social Care:

To ask His Majesty's Government whether NHS England's forthcoming quality strategy will include a new model for financial incentives in the NHS, including specialised, secondary, primary and community care.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The new NHS Quality Strategy will build on the 10-Year Health Plan and Dr Penny Dash’s review of patient safety across the health and care landscape. The 10-Year Health Plan commits to using sharper financial incentives to deliver value and improve outcomes. We expect the NHS Quality Strategy will reference, alongside other interventions, how the Department and NHS England will develop these incentives to ensure they drive high quality care across the National Health Service.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of introducing the 2018 Nutrient Profiling Model on business investment in the food and drink sector.

Answered by Ashley Dalton

As set out in our 10-Year Health Plan for England: fit for the future, we will take decisive action on the obesity crisis, easing the strain on our National Health Service and creating the healthiest generation of children ever. As part of this, the Government committed to updating the standards behind the restrictions on advertising ‘less healthy’ food or drink products on television before 9:00pm and online at any time, as well as the restrictions on the promotion of ‘less healthy’ food and drink products by location and volume price by applying the new Nutrient Profiling Model (NPM).

The advertising and promotions restrictions currently rely on the outdated NPM 2004/05. The new NPM has been updated in line with the latest dietary advice from the United Kingdom’s Scientific Advisory Committee on Nutrition, particularly in relation to free sugar and fibre. Applying it to the restrictions will strengthen these policies by bringing more products of concern for children’s health into scope.

The Government published the new NPM on 27 January. Application of the new NPM to the advertising and promotions restrictions would be subject to a full public consultation and an impact assessment of the costs to businesses and intended health outcomes.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the availability of diagnostic and treatment pathways for Tourette syndrome across Integrated Care Boards; and for what reason Tourette syndrome has not been included in the scope of the Independent Review into mental health conditions

Answered by Ashley Dalton

Integrated care boards (ICBs) are responsible for assessing local population need and commissioning appropriate diagnostic and treatment pathways for neurological conditions, including Tourette syndrome. While the Department has not undertaken a national assessment of provision across ICBs, we recognise the concerns raised about variation in diagnosis and support. To help address this, NHS England’s Getting It Right First Time (GIRFT) programme is working with ICBs to develop clear, consistent diagnostic and treatment pathways. The programme has appointed a clinical lead for children and young people's neurodevelopmental services, focusing on improving the assessment and management of Tourette syndrome.

The Independent Review into mental health conditions focuses on mental health conditions, ADHD and autism. Tourette’s is a neurological disorder and, therefore, it will be at the chair's discretion as to how far the review considers Tourette syndrome.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to HCWS1271 of 26 January 2026t on Improving Cancer Care and Early Diagnosis, when the National Cancer Plan will be published; what interim milestones have been set ahead of publication; what engagement has taken place with NHS England, Cancer Alliances and patient groups; and what mechanisms will be used to ensure delivery against the Plan’s commitments.

Answered by Ashley Dalton

The National Cancer Plan was published on the 4 February 2026.

The Department received more than 11,000 responses to a Call for Evidence alongside significant engagement with patients, families, carers, clinicians, researchers, cancer charities and voluntary groups.

Now that the National Cancer Plan is published, the Department, NHS England and the Cancer Alliances will continue to work together with partners across the healthcare landscape to ensure it is delivered, to transform cancer care and save lives.

The Government has committed to a clear accountability structure for the plan, where Cancer Alliances play a leading role to deliver it, working with local systems. A reformed National Cancer Board, jointly chaired by the Department and an independent representative, will track progress against the Plans commitments and provide regular updates to ministers. The plan includes tables at the end of each chapter, setting out when commitments should be delivered and which organisation will be responsible.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what funding provisions his Department has made in relation to the forthcoming National Tuberculosis Action Plan 2026–2031.

Answered by Ashley Dalton

The Government is currently developing the Tuberculosis National Action Plan for 2026 to 2031. The content of the plan, including any associated funding requirements, has not yet been finalised. Any proposals with financial implications will be subject to the usual cross‑Government processes, including agreement with HM Treasury. Details, with funding commitments, will be included when the plan is published.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when his Department plans to publish a timetable for implementing redress recommendations from the Cumberlege Review and the Hughes Report.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report. We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right. A timetable for a response has not yet been finalised.

I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, on what dates his Department has met with patient groups representing families affected by sodium valproate since January 2024.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The current Parliamentary Under-Secretary of State for Women's Health and Mental Health, Baroness Merron, the previous minister with responsibility for sodium valproate and pelvic mesh redress policy, held a roundtable with representatives of the sodium valproate patient groups in December 2024.

Since then, I met with relevant stakeholders at various parliamentary events. I also met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help increase the uptake of generic and biosimilar medicines to meet the objectives set out in the Government’s Life Sciences Sector Plan.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The United Kingdom is a global leader in adopting biosimilar and generic medicines, which deliver major National Health Service savings and expand patient access to effective treatments sooner.

We are working with the Medicines and Healthcare products Regulatory Agency, the National Institute for Health and Care Excellence (NICE), and NHS England to understand forthcoming biosimilars and to ensure they reach the frontline efficiently. Through NHS England’s Best Value Biologicals Framework, clinicians start patients on the most cost‑effective biologics where appropriate, and switches are made swiftly and safely. This has already delivered £1.2 billion in savings over the past three years.

As set out in the 10‑Year Health Plan and Life Sciences Sector Plan, we are streamlining regulation, improving procurement, and reducing variation in uptake. NICE’s whole‑lifecycle approach ensures clinical pathways are regularly reviewed so that patients benefit as soon as cost‑effective generics and biosimilars become available, as seen in recent cancer treatments. These actions support timely access to effective off‑patent medicines and a sustainable, competitive market for the NHS.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he plans to take to ensure parliamentary oversight of the proposed changes to NICE regulations.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The proposed amendments to the National Institute for Health and Care Excellence regulations were subject to a public consultation, which ran from 9 December 2025 to 13 January 2026. The Department is currently analysing consultation responses and will shortly finalise a statutory instrument (SI) to bring forward secondary legislation to amend the regulations.

The SI will be laid before Parliament and will be subject to the negative parliamentary procedure. The policy merits of the SI will be scrutinised by the Secondary Legislation Scrutiny Committee, in line with its terms of reference at the following link:

https://committees.parliament.uk/committee/255/secondary-legislation-scrutiny-committee/content/120278/slsc-terms-of-reference/

As is conventional, the SI will be laid before Parliament at least 21 days before coming into force to ensure Parliament has adequate time to consider it.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of expanding genetic for (a) the APOE4 gene and (b) other dementia-related risk factors in the NHS.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Pharmacogenomics and Medicine Optimisation NHS Genomic Network of Excellence convened a multidisciplinary meeting in November 2023 to support an impact assessment of potential testing for APOE-4 for prediction of risk of adverse events for lecanemab and donanemab. This group considered the evidence for expanding genomic testing for the APOE gene variants, including to inform other dementia related risk factors and concluded that there was insufficient evidence to offer genomic testing for the APOE gene variants as part of routine dementia care, risk assessment, or to first degree relatives of those with an already identified APOE variant to inform risk estimates of developing future Alzheimer's disease.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the Government plans to reinstate the Life Sciences Council.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The United Kingdom’s world leading life sciences sector is central to our Industrial Strategy, driving growth, investment, and high-quality jobs. The sector is forecast to grow by £41 billion and create 100,000 jobs by 2030, supporting our ambition to lead Europe in life sciences by 2030.

The Life Sciences Council is an important forum that brings together senior industry and Government leaders to shape the sector’s future. The Government remains committed to this partnership and is looking to convene the council in due course.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that contracts drawn up by telecare services provided by local authority-connected bodies comply with consumer protection legislation, data protection legislation, and do not disadvantage vulnerable clients.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

Telecare is not a mandatory service for local authorities, but many choose to provide a telecare service due to its benefits. Local authorities are responsible for the contractual terms of telecare services that they provide. All public authorities are required to comply with current procurement legislation when procuring goods and services. This includes legislation relating to Data Protection and Consumer rights.

The Department is developing national telecare guidelines to give commissioners, providers, and users clarity about what good telecare looks like now and in the future. This will support local authorities to commission safe, reliable, and digitally compatible telecare services that safeguard vulnerable telecare users.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve support housing-with-care for older people.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

The Government is committed to enhancing provision and choice for older people in the housing market. The Department of Health and Social Care continues to work closely with the Ministry of Housing, Communities and Local Government to consider the recommendations from the Older People’s Housing Taskforce report.

Both departments are also working together on the development of the Government’s forthcoming long-term housing strategy.

More broadly, at the Spending Review, the Government announced £39 billion for a new Social and Affordable Homes Programme over ten years from 2026/27 to 2035/36. The programme has been designed to be flexible to support the greater diversity of supply needed in the housing market, including supported housing for older people.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of children who have (a) been harmed by sodium valproate use during pregnancy and (b) received a diagnosis of Foetal Valproate Spectrum.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department does not hold information regarding the number of children that have been harmed by sodium valproate use during pregnancy, or those who have received a diagnosis of foetal valproate spectrum.

The National Disease Registration Service in NHS England collects and quality assures data about people with congenital conditions and rare conditions across the whole of England.

In the most recent official statistics on congenital conditions in England, the 2022 Congenital Condition Official Statistics Report, which contains information on congenital conditions detected in babies delivered in England between 1 January and 31 December 2022, as well as in previous publications of this series back to its inception in 2018, there were no foetus' or babies reported to have a diagnosis of fetal sodium valproate syndrome.

It is likely that while some of the individual conditions, for instance neural tube defects, cardiac, oro-facial clefts, and/or limb difference, that can be associated with this condition are recorded on the register, the overarching diagnosis of fetal sodium valproate syndrome may not yet be registered because fetal sodium valproate syndrome may take more than a year after birth to be confirmed as a diagnosis, so the number reported in any year is the minimum level in the population.

The National Disease Registration Service is assessing the feasibility and reliability of better ascertainment of fetal sodium valproate syndrome by linking the congenital condition register to primary care prescription data.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will make an assessment of the potential implications for her policies on community pharmacies of (a) business rates revaluation from April 2026 and (b) their exclusion from RHL reliefs.

Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)

The Government recognises that pharmacies are an integral ‘front door’ to the National Health Service, staffed by highly trained and skilled healthcare professionals.

In 2025/26, funding for the core community pharmacy contractual framework has been increased to £3.073 billion. This represents the largest uplift in funding of any part of the NHS, over 19% across 2024/25 and 2025/26. Additional funding is also available, for example for pharmacies delivering Pharmacy First consultations and flu and COVID-19 vaccinations.

The Department will shortly consult with Community Pharmacy England on any proposed changes to reimbursement and remuneration of pharmacy contractors for 2026/27. As part of this we will consider financial pressures on the sector.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help improve coordination between health, education, and social care services for families affected by sodium valproate.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Everyone who has been harmed from sodium valproate has our deepest sympathies.

The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support, including co-ordination with non-health care services.

In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the NHS in Newcastle and Manchester. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, better coordination of care, and reduced reliance on emergency care. Findings from the pilot will inform future decisions on the commissioning of services, subject to funding.

In addition, we work closely with the Department for Education and across the Government to ensure co-ordination between health, education, and social care services for children and their families. The Health and Opportunity Missions of the Government highlight the importance of joined up working and integrated delivery.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions he has had with Ministers in the devolved nations regarding establishing a UK wide sodium valproate redress scheme.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

Though the Patient Safety Commissioner’s report covered England-only, we recognise that any response by the Government to the recommendations of the Hughes Report in England will likely have implications for the devolved administrations and their constituents.

Government officials are therefore working closely with officials across the United Kingdom in considering the recommendations in the Hughes Report. I recently met with my counterparts across the four nations and will continue productive engagement as we progress work in this area.

The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report.

We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right.

I also met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, for what reason recommendations for a sodium valproate redress scheme have not been implemented.

Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)

The Department continues to take forward work to explore redress for those affected by pelvic mesh and sodium valproate, which includes recommendations made by the Patient Safety Commissioner in the Hughes Report. We recognise the importance of these issues for all those affected. This remains a cross-Government policy area involving multiple organisations, and given the complexity of the issues involved, it is important we get this right.

I met with the Patient Safety Commissioner in December 2025, to discuss progress following the Hughes Report and have made clear the Department’s expectation of continued, proactive engagement with the Patient Safety Commissioner and key stakeholders. I have also written to the Patient Safety Commissioner regarding further steps to be taken to improve the lives of those affected by valproate and mesh. A copy of that letter is attached.

Question to the Department of Health and Social Care:

To ask His Majesty's Government how many NHS prescriptions for (1) isotretinoin, and (2) spironolactone, have been issued in each year since 2014.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

The Prescription Cost Analysis (PCA) provides the total number of prescription items of each medicine dispensed in the community in England. The table shows the total number of items in each calendar year from 2014 to 2024, as well as the data for January to November 2025 that has been dispensed in England regardless of where prescribed:

This is based on the information within the PCA for the British National Formulary chemical substance of isotretinoin and spironolactone.

Question to the Department of Health and Social Care:

To ask His Majesty's Government what estimate they have made of the proportion of NHS GP appointments that have arisen due to mental health conditions in each of the past five years.

Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)

NHS England releases monthly statistics on general practice (GP) appointments. However, this data does not identify specific conditions addressed during individual GP appointments. Additionally, while GP clinical systems can collect and code information on conditions being treated, this information is for local management and is not shared centrally

Consequently, it is not possible to determine what proportion of National Health Service GP appointments relate to mental health conditions, or to any other specific conditions.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the Association of British Neurologists’ Workforce Report 2025, which shows that the UK has approximately 1–2 consultant neurologists per 100,000 population compared with a European average of around 6 per 100,000.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The 10-Year Health Plan, published on 3 July 2025, set out that over the next three years we will create 1,000 new specialty training posts with a focus on specialties where there is greatest need. The Government will set out its next steps on this in due course.

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of increased funding and planning for the neurology workforce; and what steps his Department is taking to increase neurology specialty training posts and consultant numbers.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The 10-Year Health Plan, published on 3 July 2025, set out that over the next three years we will create 1,000 new specialty training posts with a focus on specialties where there is greatest need. The Government will set out its next steps on this in due course.

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps is his Department taking to increase neurology specialty training posts and consultant neurologist numbers.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The 10-Year Health Plan, published on 3 July 2025, set out that over the next three years we will create 1,000 new specialty training posts with a focus on specialties where there is greatest need. The Government will set out its next steps on this in due course.

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to develop a workforce strategy to provide support for diabetes patients.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government is committed to publishing a 10 Year Workforce Plan to create a National Health Service workforce ready to deliver the transformed service set out in the 10-Year Health Plan.

The 10 Year Workforce Plan will ensure the NHS has the right people in the right places, with the right skills to care for patients, when they need it. We are working through how the plan will articulate the changes for different service areas and professional groups, such as those that support diabetes patients.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to The Bread and Flour (Amendment) (England) Regulations 2024, what steps he has taken to avoid harm to people unable to take folic acid.

Answered by Ashley Dalton

The Government laid legislation in England on 14 November 2024 to introduce the mandatory fortification of non-wholemeal wheat flour with folic acid. Similar legislation in Scotland, Wales, and Northern Ireland has also been laid. The provisions will become mandatory in December 2026.

Non-wholemeal wheat flour is already the established vehicle for mandatory fortification, as it is currently fortified with calcium, iron, niacin, and thiamine. There was a United Kingdom-wide agreement to limit folic acid fortification to flour that is already fortified, so that individuals are able to avoid fortified flour if they choose to or need to. These individuals will continue to be able to consume wholemeal flour and other non-wheat products, including gluten-free products and soy and spelt flours.

To ensure people can easily identify products that are suitable for them, added vitamins and minerals, including folic acid, must be labelled in the flour’s ingredients list. This must also be declared when fortified flour is used as an ingredient. For individuals with specific dietary needs, personalised advice from a registered dietitian or healthcare professional is recommended to help manage intakes as part of a healthy, balanced diet. An impact assessment has been published alongside the legislation, and is available at the following link:

https://www.legislation.gov.uk/uksi/2024/1162/resources

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure a robust audit of diabetes services.

Answered by Ashley Dalton

The National Diabetes Audit (NDA), and the National Peadiatric Diabetes Audit (NPDA), which are delivered in partnership with NHS England, provide comprehensive data on care processes and outcomes.

NHS Digital’s NDA dashboards and the Royal College of Paediatrics and Child Health’s NPDA dashboards are designed to help integrated care boards, providers, and paediatric diabetes units benchmark themselves and target improvements. Further information on NHS Digital’s NDA dashboards and the Royal College of Paediatrics and Child Health’s NPDA dashboards is available, respectively, at the following two links:

https://digital.nhs.uk/data-and-information/clinical-audits-and-registries/national-diabetes-audit/dashboards

https://www.rcpch.ac.uk/resources/NPDA-dashboards

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps are being taken to improve access to pulmonary rehabilitation for adults with chronic obstructive pulmonary disease living in Blaydon and Consett constituency.

Answered by Ashley Dalton

In the Blaydon and Consett area, pulmonary rehabilitation (PR) is primarily delivered by the Gateshead Health NHS Foundation Trust. Since April 2024, the trust's physiotherapy and occupational therapy services have undertaken a comprehensive redesign of the PR service. This restructure aims to ensure equity of access for all patients across the referral catchment area and to guarantee consistency in both the clinical content and delivery of the course.

The redesigned service is now fully operational, and the trust will be monitoring patient outcomes and attendance figures throughout the coming year to ensure the new structure delivers the intended improvements in patient health and service reach.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to reduce levels of burnout of NHS staff.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The health and wellbeing of all National Health Service staff is a top priority.  NHS organisations have a responsibility to create supportive working environments for staff, ensuring they have the conditions they need to thrive, including access to high quality health and wellbeing support.

At a national level, NHS staff have access to the SHOUT helpline for crisis support alongside the Practitioner Health service for more complex mental health and wellbeing support, including trauma and addiction.

The Government is committed to publishing a 10 Year Workforce Plan which will have a focus on supporting our hardworking and dedicated healthcare professionals. This includes the development of a new set of staff standards for modern employment and the roll-out of Staff Treatment Hubs that will ensure staff have access to high quality support for occupational health, including support for mental health and back conditions.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of the absence of a regular, comprehensive national workforce census on neurology workforce planning; and if he will commit to establishing such a census.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

No such assessment has been made. NHS England already publishes well-established official statistics on the medical neurology workforce, therefore there are no plans to introduce a census.

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Department for Science, Innovation and Technology on the potential impact of a modern service framework for respiratory conditions on the UK’s life sciences ecosystem, including the scaling up of the adoption of new medicines and innovations for lung conditions.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government will consider long-term conditions for future waves of modern service frameworks (MSFs), including respiratory conditions. The criteria for determining other conditions for future MSFs will be based on where there is the potential for rapid and significant improvements in quality of care and productivity. After the initial wave of MSFs is complete, the National Quality Board will determine the conditions to prioritise for new MSFs as part of its work programme.

NHS England and the Department of Health and Social Care are working with the Department for Science, Innovation and Technology to explore innovation and policy prioritisation in respiratory health, including the cross‑Government alignment that may be required.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what is the timeline for determining the second wave of Modern Service Frameworks, and what assessment he has made of the potential merits of including respiratory conditions.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government will consider long-term conditions for future waves of modern service frameworks (MSFs), including respiratory conditions. The criteria for determining other conditions for future MSFs will be based on where there is the potential for rapid and significant improvements in quality of care and productivity. After the initial wave of MSFs is complete, the National Quality Board will determine the conditions to prioritise for new MSFs as part of its work programme.

NHS England and the Department of Health and Social Care are working with the Department for Science, Innovation and Technology to explore innovation and policy prioritisation in respiratory health, including the cross‑Government alignment that may be required.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that overseas visitor charging regulations are applied uniformly across NHS trusts.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The overseas visitor charging regulations apply to all National Health Service trusts in England. The Department is working closely with NHS England to ensure the NHS (Charges to Overseas Visitors) Regulations 2015 are applied fairly and consistently across all NHS trusts.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what specific mechanisms will enable HM Revenue and Customs and Border Force to verify compliance with the vaping product registration scheme at the point of import; and whether registration numbers will be required on customs documentation.

Answered by Ashley Dalton

Officials in the Department of Health and Social Care regularly meet with officials from other departments, including HM Revenue and Customs and Border Force, to share intelligence and ensure a coordinated approach to the enforcement of our rules on vaping products. This coordinated approach to enforcement will continue once the Tobacco and Vapes Bill becomes law and in the development of subsequent regulations.

We launched a call for evidence in October 2025 which sought further detail on the existing product notification schemes and where registration could go further than current requirements. The call for evidence closed on 3 December 2025, and we are in the process of analysing the responses. Policy proposals will be subject to further consultation before regulations are made with sufficient lead time for businesses to adjust to the new requirements.

The Government intends to implement vaping duty stamps alongside the Vaping Products Duty commencing in October 2026, in line with HM Revenue and Customs’ strategic objective of making it easy to get tax right and hard to bend or break the rules. Vaping duty stamps will support both enforcement bodies and industry in identifying products that are non-duty paid, therefore illicit. We will work with HM Revenue and Customs to ensure a joined-up approach, where appropriate.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase the number of nurses and midwives.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

The Government is committed to publishing a 10 Year Workforce Plan to set out action to create a workforce ready to deliver the transformed service set out in the 10-Year Health Plan. The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what formal intergovernmental mechanisms are in place to coordinate enforcement of the vaping product registration and testing regime across the four nations of the United Kingdom.

Answered by Ashley Dalton

Powers in the Tobacco and Vapes Bill allow us to develop a new registration and testing scheme for all vape, nicotine, and tobacco products. These powers will apply across the United Kingdom, and it is therefore vital that the future registration scheme works for all nations.

We are in the process of developing the new registration scheme and we launched a call for evidence in October 2025 which sought further detail on the existing product notification schemes and where registration could go further than current requirements. The call for evidence closed on 3 December 2025, and we are in the process of analysing the responses.

We are working closely with the devolved administrations on all future regulations and officials meet with them regularly to discuss a range of issues. This includes on the registration scheme and the coordination across the United Kingdom that will be a crucial part of any considerations. Policy proposals will be subject to further consultation before regulations are made with sufficient lead time for businesses to adjust to the new requirements.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he expects the vaping product registration scheme to be fully operational before the commencement of the Vaping Products Duty in October 2026; and what contingency arrangements will apply if implementation timetables differ.

Answered by Ashley Dalton

Powers in the Tobacco and Vapes Bill allow us to develop a new registration and testing scheme for all vape, nicotine, and tobacco products. This will replace the current notification system and competent authority function which will remain in place until the new regulations. Our current intention is for the new scheme to be operational by the end of this Parliament.

While they are linked, there are differences between the future registration scheme and the Vaping Products Duty, commencing in October 2026, which will provide civil and criminal powers for HM Revenue and Customs to assess for duty and seize products and equipment used to produce or transport illicit products.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether the Office for Product Safety and Standards will oversee the vaping product registration scheme.

Answered by Ashley Dalton

Officials from the Department of Health and Social Care and the Office for Product Safety and Standards are considering whether the Office for Product Safety and Standards would be best placed to oversee the future register.

Officials in Department of Health and Social Care and the Office for Product Safety and Standards have agreed, at a working level, an interim Memorandum of Understanding to review whether the Office for Product Safety and Standards is a suitable home for the future scheme. We expect to consult on proposals for the product registration scheme later this year.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what support exists for children under 16 diagnosed with Long Covid.

Answered by Ashley Dalton

NHS England has invested significantly in supporting people with long COVID. This includes setting up specialist long COVID services nationwide for adults, and children and young people, and investing in ensuring general practice (GP) teams are equipped to support people affected by the condition. Since April 2024, in line with the National Health Service operating framework and the establishment of integrated care systems, the commissioning of services to support patients with long COVID, including children, has been the responsibility of integrated care boards. Where local long COVID services are not available, children and young people with long COVID symptoms should see their GP, who will be able to refer them to alternative existing services depending on their clinical needs.

The National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC), part of UK Research and Innovation, are committed to funding high-quality research to understand the causes, consequences, and treatment for long COVID.  This includes a new funding opportunity for a development award which is focussed on the feasibility of a phase 2 platform clinical trial that tests multiple repurposed pharmaceutical and/or non-pharmacological interventions for the treatment of myalgic encephalomyelitis, also known as chronic fatigue syndrome, and long COVID.

We have also funded research specifically focused on long COVID in children and young people, including the approximate £1.9 million CLoCk study jointly funded by the NIHR and the MRC. The study developed an agreed definition of long COVID in children and young people and associated symptoms, to improve understanding of the condition and help harmonise research.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether he plans to introduce at-home test kits for cervical smears.

Answered by Ashley Dalton

The Government has announced the introduction of human papilloma virus (HPV) self-testing in the National Health Service cervical screening programme for the under-screened population in England. The NHS has begun planning an in-service evaluation (ISE) of HPV self-testing in the wider population.

The purpose of the ISE is to ensure that the self-test is acceptable, accurate, and feasible compared with a clinician collected specimen, and to evaluate its impact on cervical screening uptake and ensure that the programme continues to prevent the same number of cancers. The findings of the ISE will inform any future UK National Screening Committee recommendation to ministers to offer self-testing across the whole population, alongside clinician-led screening.

Found: Letter from Baroness Merron, Parliamentary Under-Secretary of State at Department of Health and Social Care

Found: with digital technology suppliers HC 640 26th Tackling Violence against Women and Girls HC 644 25th DHSC

Found: Department of Education, Ministry of Housing, Communities & Local Government and Department of Health and Social Care

Found: (DHSC) consider these trends when devising their strategies, such as the 10 year Health

Found: Between September and October 2023, the Department of Health and Social Care held a public consultation

Found: Breast implant associated anaplastic large cell lymphoma (BIA-ALCL), July 2017 42 Department of Health and Social Care

Found: fertility clinics being mandated to report long-term outcomes to the HFEA, which must report it to DHSC

Found: I know my colleagues in the Welsh Government and across the Department of Health and Social Care, as

Found: well as some representatives from different government departments, including the Department of Health and Social Care

Found: Work and Pensions, Lorraine Jackson, Director, Joint Work and Health Directorate, Department of Health and Social Care

Question to the Department for Education:

To ask the Secretary of State for Education, what steps is she taking to assess the potential impact of screen time on the development of children under 5.

Answered by Olivia Bailey - Parliamentary Under-Secretary of State (Department for Education) (Equalities)

The department is commissioning a systematic review of evidence that enables causal inference, rather than just correlation, to better understand how screentime impacts children and young people, including under fives. We are planning a further programme of research on the impact of digital technologies on children, including under fives, to commence in April 2026.

There is an existing suite of longitudinal studies, ‘education and outcomes pathways studies’, which are tracking home learning, screen use, and educational and wellbeing outcomes in the early years phase of education, as well as primary and secondary more widely.

A report including screen time and digital media use for children aged 2 was published on 11 January 2026 here: https://www.gov.uk/government/publications/children-of-the-2020s-second-survey-of-families-at-age-2. Further reports will be published in due course as the studies continue.

The department and The Department of Health and Social Care are jointly working to produce and publish new practical, evidence informed guidance on screentime for early years (0-5) by April 2026. An Early Years Screen Time Advisory Group of child health and development specialists has been convened to shape the guidance, which will also be informed by the perspectives of parents and carers.

The Advisory Group has launched a two-week call for evidence to inform the guidance. By drawing on robust evidence and expertise, the review aims to ensure that the resulting guidance for parents is credible, reliable and grounded in the best available science.

In addition, the Department for Science, Innovation and Technology is launching a consultation on children's social media use and bans phones in schools.

Question to the Department for Transport:

To ask the Secretary of State for Transport, what discussions her Department has had with the Department of Health and Social Care on promoting regular sight tests for drivers as part of the Government’s road safety strategy.

Answered by Lilian Greenwood - Government Whip, Lord Commissioner of HM Treasury

Both Department for Transport and Driving and Vehicle Licensing Agency officials have worked with officials from the Department of Health and Social Care (DHSC) while developing the proposed changes to eyesight testing for older drivers, and we will continue to engage with the DHSC as our policies develop further.

The Department for Transport fully supports the NHS’s recommendation that adults should have their eyes tested every two years.

All drivers, regardless of age, have a legal responsibility to inform the Driver and Vehicle Licensing Agency (DVLA) if they develop a medical condition that may affect their ability to drive.

On 7 January 2026 we published our new Road Safety Strategy, setting out our vision for a safer future on our roads for all. Alongside the strategy, we launched five consultations including a consultation on introducing mandatory eyesight testing for older drivers.

Once the consultation has concluded, we will publish our response in due course.

Found: British Association of Social Workers.51 The steering group says it is supported by the Department of Health and Social care

Found: DHSC expects to spend £316 million ODA for 2025/26, a £15 million reduction compared to its initial

Found: Answering member: Dr Zubir Ahmed | Department: Department of Health and Social Care The Government

Found: programme over the next three years, in partnership with the Department for Health and Social Care (DHSC

Found: programme over the next three years, in partnership with the Department for Health and Social Care (DHSC

Found: and Language Therapists and Speech and Language UK, as well as NHS England and the Department of Health and Social Care

Found: partnerships for supporting neurodivergent needs between education, health, and social care DfE and DHSC

Found: (VSMs) working in the NHS and Executive and Senior Managers (ESMs) working in the Department of Health and Social Care

Found: children under 5 who have been identified as having complex needs, we will work with the Department of Health and Social Care

Found: children under 5 who have been identified as having complex needs, we will work with the Department of Health and Social Care

Found: is absent because their travel or attendance at school would be contrary to any guidance from the DHSC

Found: The MHRA is an executive agency of the Department of Health and Social Care.   

Found: The MHRA is an executive agency of the Department of Health and Social Care.  

Found: The MHRA is an executive agency of the Department of Health and Social Care. 

Found: (VSMs) working in the NHS and Executive and Senior Managers (ESMs) working in the Department of Health and Social Care

Found: year-olds Date of publication 2026-02-17 00:00:00 Feedback It is important that the Department of Health and Social Care

Found: Office for Health Improvements and Disparities (OHID) in the Department for Health and Social Care (DHSC

Found: MHRA may also share your responses, when anonymised, with Department of Health and Social Care, Government

Found: Comments Source of funding: UK Department of Health and Social Care (DHSC).

Found: Using figures from the Department of Health and Social Care (DHSC) in England in 2015, the estimated

Found: Subsequent pharmacological management FINAL [Feb 2026] FINAL Source of funding: UK Department of Health and Social Care

Found: powder for concentrate for solution for infusion (pending confirmation with the Department of Health and Social Care

Found: answers and statements - Ear, Nose and Throat Conditions: Surgery - Question for Department of Health and Social Care

Found: Next steps The Department of Health and Social Care (DHSC), NHS England and NHS Supply Chain will continue

Found: DHSC data ingestion As part of the merger of NHS England and the Department of Health and Social Care

Found: Darnall Well Being Debdale Specialist Care Ltd Department of Health - Northern Ireland Department of Health and Social Care

Found: pharmacological management DRAFT FOR CONSULTATION [Aug 2025] 10 Source of funding: UK Department of Health and Social Care

Found: Darnall Well Being Debdale Specialist Care Ltd Department of Health - Northern Ireland Department of Health and Social Care

Found: Comments Source of funding: UK Department of Health and Social Care (DHSC).

Found: powder for concentrate for solution for infusion (pending confirmation with the Department of Health and Social Care

Found: consultation Dupilumab for treating severe chronic rhinosinusitis with nasal polyps The Department of Health and Social Care

Found: with pomalidomide and dexamethasone for previously treated multiple myeloma The Department of Health and Social Care

Found: Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) The Department of Health and Social Care

Found: Society • Royal Society of Medicine • UK Clinical Pharmacy Association Others • Department of Health and Social Care

Found: Society Royal Society of Medicine UK Clinical Pharmacy Association Others Department of Health and Social Care

Found: Pharmacy Association • UK Myeloma Society • UK Oncology Nursing Society Others • Department of Health and Social Care

Found: Cambridge University Hospitals NHS Trust – Addenbrooke’s Lysosomal Disorders Unit • Department of Health and Social Care

Found: Cambridge University Hospitals NHS Trust – Addenbrooke’s Lysosomal Disorders Unit • Department of Health and Social Care

Found: Foundation Trust Darnall Well Being Department of Epidemiology and Public Health Department of Health and Social Care

Found: Trust Darlington Primary Care Network Darnall Well Being Debdale Specialist Care Ltd Department of Health and Social Care

Found: Trust Darlington Primary Care Network Darnall Well Being Debdale Specialist Care Ltd Department of Health and Social Care

Found: Department of Health and Social Care.

Found: Trust Darlington Primary Care Network Darnall Well Being Debdale Specialist Care Ltd Department of Health and Social Care

Found: Trust Darlington Primary Care Network Darnall Well Being Debdale Specialist Care Ltd Department of Health and Social Care

Found: Cardiac Network CWHHE Collaborative CCGs Cybex Ventures Daiichi Sankyo UK Decideum Department of Health and Social Care

Found: on ECD response  Commercial offering  Battens Disease Family Association The Department of Health and Social Care

Found: and the Office for Health Improvement and Disparities (OHID), which is part of the Department of Health and Social Care

Found: National Institute for Health and Care Research (NIHR), the research delivery arm of the Department of Health and Social Care

Found: Scottish Infected Blood Support Scheme interim payments which are funded from the UK Department of Health and Social Care

Found: Scottish Infected Blood Support Scheme interim payments which are funded from the UK Department of Health and Social Care

Found: Defra, Department of Health and Social Care (DHSC), DWP DAERA, Department of Health (DoH) N/A Rural

Found: Defra, Department of Health and Social Care (DHSC), DWP DAERA, Department of Health (DoH) N/A Rural

Found: Continuing Professional Development DAERA Department of Agriculture, Environment and Rural Affairs DHSC